Day: December 29, 2025

Company AnnouncementGenmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and increasingly competitive landscape This decision does not impact Genmab’s full‑year 2025 financial guidanceCOPENHAGEN, Denmark; December 29, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY® (epcoritamab),...

CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each pre-funded warrant. The closing of the offering is expected to take place on or about December 30, 2025, subject to the satisfaction of customary closing conditions. The gross...

KH Group Plc Stock Exchange Release 29 December 2025 at 2:45 pm EET KH Group Plc – Managers’ Transactions – Juha Karttunen ____________________________________________ Person subject to the notification requirementName: Juha KarttunenPosition: Member of the Board/Deputy memberIssuer: KH Group OyjLEI: 743700F6CLX8JMYDEP21Notification type: INITIAL NOTIFICATIONReference number: 135629/5/4____________________________________________ Transaction date: 2025-12-22Outside a trading venueInstrument type: SHAREISIN: FI0009008924Nature of transaction: ACQUISITION Transaction details(1): Volume: 4322 Unit price: 0.397 EUR(2): Volume: 2 Unit price: 0.404 EUR(3): Volume: 5080 Unit price: 0.397 EUR(4): Volume: 439 Unit price: 0.397 EUR(5): Volume: 5471 Unit price: 0.397 EUR(6): Volume: 5000 Unit price: 0.4 EUR(7): Volume: 1600 Unit price:...

Deployment of up to €30 million of Partner-committed capital, to be released over time in three potential tranches of €10 million each. First project expected to be a green hydrogen production facility in Spain in 2026.Dublin, Ireland, Dec. 29, 2025 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (NASDAQ:HTOO) (“Fusion Fuel” or the “Company”), today announced that Bright Hydrogen Solutions Limited (“BrightHy Solutions”), a wholly-owned subsidiary of Fusion Fuel, has signed agreements with a green energy technologies provider (the “Partner”) establishing Bright Hydrogen Holding Company Limited (“Bright Hydrogen Holding”) as a dedicated platform for the development, financing and delivery of industrial-scale hydrogen projects, with up to €30 million in financing by the Partner. The signing of the agreements marks the commercial evolution...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-4800 (anti-Borrelia OspA mAb) available for clinical trials in early 2027 Approximately 70 million people that live, work or vacation in areas of the U.S. in which Lyme disease is endemic could potentially benefit from pre-exposure prophylaxis CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today announced program updates on TNX-4800 (formerly known as mAb 2217LS)1,2, which is a long-acting human monoclonal antibody (mAb) that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the causative agent of...

Company to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline Raanana, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that its Board of Directors has decided to explore realistic investment opportunities in revenue-generating real assets. The Company remains fully committed to its core medical device activities, continuing to advance product development, preclinical and clinical studies, and regulatory progress – including products such as PL-14 (allergy blocker), PL-16 (viral blocker), and the Trap & Target platform for intranasal drug delivery. In parallel, leveraging the Company’s strong cash position, the...

New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission LOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. “Our original third-party manufacturing vendor has made significant progress toward regaining FDA compliance, allowing us to resubmit the OLC NDA as planned,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With a cash...